Company news
CDT Equity Inc. news in 2026
CDT Equity Inc.'s news releases, calls and decks from 2026, newest first.
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
October 30, 2026
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
October 27, 2026
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
October 14, 2026
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
September 29, 2026
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
September 18, 2026
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
September 10, 2026
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
September 2, 2026
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
September 1, 2026
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
August 25, 2026
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
August 3, 2026
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
July 20, 2026
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
June 26, 2026
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
June 18, 2026
CDT Equity Announces Debt Update and New Loan Facility
June 16, 2026
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
May 28, 2026
CDT Announces Canadian Patent for AZD5904 in Male Infertility
May 27, 2026
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
May 6, 2026
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
April 15, 2026
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
March 25, 2026
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
March 23, 2026
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
March 17, 2026
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
March 4, 2026
CDT Positions for Transformational Growth
March 4, 2026
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
February 24, 2026
CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy
February 20, 2026
CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy
January 1, 2026